Bevacizumab and everolimus in renal cancer: a rational way forward

J Clin Oncol. 2010 Nov 20;28(33):e692-3; author reply e694. doi: 10.1200/JCO.2010.30.7934. Epub 2010 Oct 12.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / mortality
  • Everolimus
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / mortality
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Everolimus
  • Sirolimus